A new breast cancer drug which extends women's lives by almost six months could be blocked from routine NHS access because it is too expensive, a health watchdog says.
Kadcyla, manufactured by Roche, can cost more than £90,000 per patient and is not effective enough to justify the price the NHS is being asked to pay, the National Institute for Health and Care Excellence (Nice) said.
The watchdog, which decides which new medicines are cost effective, said its guidance for the drug, also known as trastuzumab emtansine, was in draft form and is now up for public consultation.
If the recommendations are adopted, patients would have to apply to their local NHS and to the Cancer Drugs Fund (CDF) for the drug, a Nice spokeswoman said.
More top news
The late Bernard Jordan, who 'escaped' from his care home to travel to the D-Day commemorations, has left his entire estate to the RNLI.
UK to be "very cold indeed" over the coming days due to bitter northeasterly winds.
Luis Figo will run a campaign for change after announcing his intention to challenge Sepp Blatter for the Fifa presidency